Utama › Sistem Imun dan Gangguan › Oregon
Kajian klinikal Sistem Imun dan Gangguan di Oregon
9 kajian untuk Sistem Imun dan Gangguan sedang mencari peserta di lokasi di Oregon.
Bandar di Oregon
Teks kajian rasmi (Bahasa Inggeris)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Oregon Health & Science University, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- dan 9 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07075185A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
Mengambil pesertaFasa 2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Providence Neurological Specialties West, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Oregon Health and Science University, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.